• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Acadia Pharmaceuticals Set to Join S&P SmallCap 600

    12/30/24 5:37:00 PM ET
    $ACAD
    $IBTX
    $SPGI
    $SSB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Banks
    Finance
    Get the next $ACAD alert in real time by email

    NEW YORK, Dec. 30, 2024 /PRNewswire/ -- Acadia Pharmaceuticals Inc. (NASD: ACAD) will replace Independent Bank Group Inc. (NASD: IBTX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 3, 2025. S&P MidCap 400 constituent SouthState Corp. (NYSE:SSB) is acquiring Independent Bank Group in a deal expected to close soon pending final conditions.

    Following is a summary of the change that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    Jan 3, 2025

    S&P SmallCap 600

    Addition

    Acadia Pharmaceuticals

    ACAD

    Health Care

    Jan 3, 2025

    S&P SmallCap 600

    Deletion

    Independent Bank Group

    IBTX

    Financials

    For more information about S&P Dow Jones Indices, please visit www.spdji.com 

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com. 

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected] 

    Media Inquiries

    [email protected] 

    Cision View original content:https://www.prnewswire.com/news-releases/acadia-pharmaceuticals-set-to-join-sp-smallcap-600-302340435.html

    SOURCE S&P Dow Jones Indices

    Get the next $ACAD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACAD
    $IBTX
    $SPGI
    $SSB

    CompanyDatePrice TargetRatingAnalyst
    SouthState Bank Corporation
    $SSB
    3/19/2026$110.00Market Perform → Outperform
    Hovde Group
    ACADIA Pharmaceuticals Inc.
    $ACAD
    2/24/2026$33.00Outperform
    Wolfe Research
    ACADIA Pharmaceuticals Inc.
    $ACAD
    2/23/2026$35.00Neutral → Outperform
    Mizuho
    S&P Global Inc.
    $SPGI
    2/17/2026$575.00Buy
    BofA Securities
    SouthState Bank Corporation
    $SSB
    12/12/2025$115.00Overweight
    Analyst
    ACADIA Pharmaceuticals Inc.
    $ACAD
    10/21/2025$33.00Buy
    Citigroup
    S&P Global Inc.
    $SPGI
    10/1/2025$540.00Buy
    Seaport Research Partners
    SouthState Bank Corporation
    $SSB
    9/25/2025$127.00Buy
    TD Cowen
    More analyst ratings

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Joly Hubert bought $997,459 worth of shares (2,500 units at $398.98), increasing direct ownership by 1,515% to 2,665 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    2/12/26 4:01:28 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    President, S&P Global Mobility Eager William W bought $11,917 worth of shares (23 units at $517.58), increasing direct ownership by 0.26% to 8,724 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    1/15/26 4:01:18 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Director Smith G Stacy bought $230,750 worth of shares (2,500 units at $92.30), increasing direct ownership by 7% to 39,546 units (SEC Form 4)

    4 - SouthState Corp (0000764038) (Issuer)

    8/4/25 10:55:38 AM ET
    $SSB
    Major Banks
    Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Poole Jonathan

    4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

    3/20/26 6:01:17 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Poole Jonathan

    3 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

    3/20/26 6:00:14 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Brooks Renee R gifted 2,128 shares, decreasing direct ownership by 5% to 37,854 units (SEC Form 4)

    4 - SouthState Bank Corp (0000764038) (Issuer)

    3/13/26 4:04:34 PM ET
    $SSB
    Major Banks
    Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    SEC Filings

    View All

    ACADIA Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update

    8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)

    3/4/26 8:56:44 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by SouthState Bank Corporation

    DEFA14A - SouthState Bank Corp (0000764038) (Filer)

    3/3/26 9:01:57 AM ET
    $SSB
    Major Banks
    Finance

    SEC Form DEF 14A filed by SouthState Bank Corporation

    DEF 14A - SouthState Bank Corp (0000764038) (Filer)

    3/3/26 9:00:56 AM ET
    $SSB
    Major Banks
    Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Vita Coco Company Set to Join S&P SmallCap 600

    NEW YORK, March 20, 2026 /PRNewswire/ -- The Vita Coco Company Inc. (NASD: COCO) will replace TEGNA Inc. (NYSE:TGNA) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, March 25. S&P MidCap 400 constituent Nexstar Media Group Inc. (NASD: NXST) has acquired TEGNA in a deal that closed today, March 20. Following is a summary of the change that will take place prior to the open of trading on the effective date:Effective DateIndex Name       ActionCompany NameTickerGICS SectorMarch 25, 2026S&P SmallCap 600AdditionThe Vita Coco CompanyCOCOConsumer StaplesMarch 25, 2026S&P SmallCap 600DeletionTEGNATGNACommunication ServicesABOUT S&P DOW JONES INDICESS&P Dow Jones Indice

    3/20/26 6:06:00 PM ET
    $COCO
    $NXST
    $SPGI
    Beverages (Production/Distribution)
    Consumer Staples
    Broadcasting
    Industrials

    S&P Global: Era of Linear Energy Transition Has Ended as AI Demand and Geopolitics Reshape Markets

    New journal published ahead of 44th Annual CERAWeek explores the competing pressures driving energy markets and the impact of ongoing geopolitical uncertaintyAnalysis published amidst ongoing war in the Middle East, one of the most historically important moments in the global energy marketsNEW YORK, March 20, 2026 /PRNewswire/ -- S&P Global today released new research examining how the global energy landscape is being reshaped by geopolitics and competing priorities of affordability, reliability, competitiveness, and decarbonization.  The edition went to press amidst the evolving war in the Middle East with unprecedented volatility in energy markets.

    3/20/26 1:15:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Nobel Prize Winner Maria Corina Machado to Address CERAWeek by S&P Global in Houston, March 23-27

    World's preeminent energy conference to focus on 'Convergence and Competition: Energy, Technology and Geopolitics.' Learn more at www.ceraweek.comHOUSTON, March 19, 2026 /PRNewswire/ -- Nobel Laureate Maria Corina Machado will address delegates at the 44th annual CERAWeek by S&P Global, March 23-27 in Houston. She will join the world's energy industry leaders, experts, government officials and policymakers, as well as leaders from the technology, financial and industrial communities addressing this year's conference. In shaping a vision for Venezuela's future, Ms. Machado has be

    3/19/26 11:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-9) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy

    9/18/23 10:47:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-12) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy

    9/18/23 10:40:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DAYBUE issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug DAYBUE (ORIG-1) with active ingredient TROFINETIDE has changed to 'Approval' on 03/10/2023. Application Category: NDA, Application Number: 217026, Application Classification: Type 1 - New Molecular Entity

    3/13/23 10:37:07 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    SouthState Bank Corp upgraded by Hovde Group with a new price target

    Hovde Group upgraded SouthState Bank Corp from Market Perform to Outperform and set a new price target of $110.00

    3/19/26 8:23:34 AM ET
    $SSB
    Major Banks
    Finance

    Wolfe Research initiated coverage on ACADIA Pharmaceuticals with a new price target

    Wolfe Research initiated coverage of ACADIA Pharmaceuticals with a rating of Outperform and set a new price target of $33.00

    2/24/26 7:44:56 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACADIA Pharmaceuticals upgraded by Mizuho with a new price target

    Mizuho upgraded ACADIA Pharmaceuticals from Neutral to Outperform and set a new price target of $35.00

    2/23/26 8:28:41 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Leadership Updates

    Live Leadership Updates

    View All

    The Vita Coco Company Set to Join S&P SmallCap 600

    NEW YORK, March 20, 2026 /PRNewswire/ -- The Vita Coco Company Inc. (NASD: COCO) will replace TEGNA Inc. (NYSE:TGNA) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, March 25. S&P MidCap 400 constituent Nexstar Media Group Inc. (NASD: NXST) has acquired TEGNA in a deal that closed today, March 20. Following is a summary of the change that will take place prior to the open of trading on the effective date:Effective DateIndex Name       ActionCompany NameTickerGICS SectorMarch 25, 2026S&P SmallCap 600AdditionThe Vita Coco CompanyCOCOConsumer StaplesMarch 25, 2026S&P SmallCap 600DeletionTEGNATGNACommunication ServicesABOUT S&P DOW JONES INDICESS&P Dow Jones Indice

    3/20/26 6:06:00 PM ET
    $COCO
    $NXST
    $SPGI
    Beverages (Production/Distribution)
    Consumer Staples
    Broadcasting
    Industrials

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Company's Audit Committee and brings deep biopharmaceutical finance leadership experience in supporting global growth and innovation across multiple therapeutic areas and modalities. "Jonathan brings extensive biotechnology corporate leadership experience and a proven track record of supporting significant business growth across complex, global organizations," said Stephen R. Biggar, M.D., Ph.D., Chairman of Acadia's Board of Directors. "His appointment further strengthens the Board's financial and operational expert

    3/3/26 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Financials

    Live finance-specific insights

    View All

    S&P Global Acquires Enertel AI Corporation to Enhance Power Market Offering

    Strengthens Power and Renewables Portfolio with Combined Long-Term and Short-Term Insights Delivers Best-in-Class AI-Powered Nodal Price Forecasts and Decision Tools for Physical Power Traders, Utilities and Asset Operators NEW YORK, March 18, 2026 /PRNewswire/ -- S&P Global today announced the completion of its acquisition of Enertel AI Corporation, a company specializing in AI and machine learning-driven short-term power price forecasting for North American electricity markets. These new capabilities will join S&P Global's Energy division which has established itself as the au

    3/18/26 8:30:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global Enhances Capital IQ Pro with Expanded Fixed Income, Biopharma and Private Markets Data Content and AI Capabilities

    Drift AI acquisition and the integration of ProntoNLP boost platform's GenAI tooling for enhanced client impactAdds ProntoNLP sentiment analysis to AI-powered Document Intelligence and over 4 million structured securities to accelerate financial analysis Acquires Drift AI to integrate natural language financial modeling into Capital IQ Pro Excel Plugin NEW YORK, March 12, 2026 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced significant enhancements to its flagship S&P Capital IQ Pro platform that incorporate advanced artificial intelligence capabilities and expanded datasets to accelerate financial analysis and decision making. The updates include the addition of ProntoNLP analytics a

    3/12/26 8:30:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global Reports Fourth Quarter and Full-Year 2025 Results

    NEW YORK, Feb. 10, 2026 /PRNewswire/ -- S&P Global (NYSE:SPGI) today reported fourth quarter and full-year 2025 results. The Company's earnings release and supplemental materials are available at http://investor.spglobal.com/Quarterly-Earnings.  Supplemental Information/Conference Call/Webcast Details:  The Company's senior management will review the fourth quarter and full-year 2025 earnings results on a conference call scheduled for today, February 10, at 8:30 a.m. ET. Additional information presented on the conference call, and the Company's supplemental slide content may b

    2/10/26 7:22:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SouthState Corporation

    SC 13G/A - SouthState Corp (0000764038) (Subject)

    11/14/24 1:28:29 PM ET
    $SSB
    Major Banks
    Finance

    Amendment: SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc.

    SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)

    11/14/24 6:48:52 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SouthState Corporation

    SC 13G - SouthState Corp (0000764038) (Subject)

    2/14/24 10:04:34 AM ET
    $SSB
    Major Banks
    Finance